The FDA revoked the clearance of the anti-VEGF antibody bevacizumab because it did not affect the advancement of breast cancer [166] which may entail additional angiogenic growth factors being expressed in a HIF-1-dependent way. The gene discussed is HIF1A; the disease is breast carcinoma.